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Abstract 
 
Aims: The progressive accumulation of cells in pulmonary vascular walls is a key 
pathological feature of pulmonary arterial hypertension (PAH) that results in narrowing of the 
vessel lumen, but treatments targeting this mechanism are lacking. The C-X-C motif 
chemokine 12 (CXCL12) appears to be crucial in these processes. We investigated the 
activity of two CXCL12 neutraligands on experimental PH, using two complementary animal 
models.  
Methods and Results: Male Wistar rats were injected with monocrotaline or were subjected 
to SU5416 followed by 3-week Hypoxia to induce severe PH. After PH establishment, 
assessed by pulsed-wave Doppler echocardiography, MCT-injected or SuHx rats were 
randomized to receive CXCL12 neutraligands chalcone 4 or LIT-927 (100 mg/kg/day), the 
CXCR4 antagonist AMD3100 (5 mg/kg/day), or vehicle, for 2 or 3 weeks respectively. At 
the end of these treatment periods, echocardiographic and hemodynamic measurements were 
performed and tissue samples were collected for protein expression and histological analysis. 
Daily treatment of MCT-injected or SuHx rats with established PH with chalcone 4 or LIT-
927 partially reversed established PH, reducing total pulmonary vascular resistance, and 
remodelling of pulmonary arterioles. Consistent with these observations, we found that 
neutralization of CXCL12 attenuates right ventricular hypertrophy, pulmonary vascular 
remodelling, and decreases PA-SMC proliferation in lungs of MCT-injected rats and SuHx 
rats. Importantly, CXCL12 neutralization with either chalcone 4 or LIT-927 inhibited the 
migration of PA-SMCs and pericytes in vitro with a better efficacy than AMD3100. Finally, 
we found that CXCL12 neutralization decreases vascular pericyte coverage and macrophage 
infiltration in lungs of both MCT-injected and SuHx rats. 
Conclusion: We report here a greater beneficial effect of CXCL12 neutralization versus the 
conventional CXCR4 blockade with AMD3100 in the MCT and SuHx rat models of severe 
PH, supporting a role for CXCL12 in the progression of vascular complications in PH and 
opening to new therapeutic options. 
 
Keywords: Pulmonary arterial hypertension, vascular remodelling, animal model, 
therapeutic target, stromal cell-derived factor 1, chemokine 
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Abbreviations: 
3G5, 3G5-reactive ganglioside antigen 
AU, arbitrary unit 
CCL2, chemokine ligand 2  
CO, cardiac output 
CXCL12, C-X-C motif chemokine 12 
CXCR4, C-X-C motif chemokine receptor 4 
CXCR7, C-X-C motif chemokine receptor 7 
DAPI, 4′,6-diamidino-2-phenylindole 
ERK, extracellular signal–regulated kinase 
H&E, hematoxylin eosin 
IL, interleukin 
LV, left ventricle 
MCT, monocrotaline 
MIF, macrophage migration inhibitory factor 
mPAP, mean pulmonary arterial pressure 
NG2, nerve/glial antigen 2 
pAKT, phosphorylated protein kinase B 
pERK, phosphorylated extracellular signal–regulated kinase 
PAH, pulmonary arterial hypertension 
PH, pulmonary hypertension 
PVR, pulmonary vascular resistance 
RV, right ventricle 
S, septum 
SDF1, stromal cell-derived factor 1 
SU or SU5416, 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one 
SuHx, SU5416 plus chronic hypoxia 
TPVR, total pulmonary vascular resistance 
α-SMA, α-smooth muscle actin  
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Introduction 
Pulmonary arterial hypertension (PAH) is a severe and incurable cardiopulmonary condition 
characterized by a marked and sustained increase in mean pulmonary artery pressure 
(mPAP) that ultimately leads to right ventricular failure and death 1, 2. Despite recent 
progresses, most patients still die from this life-threatening condition or fail to respond 
adequately to medical therapy with a 5-year survival of 59% 3. Therefore, there is a 
substantial need to develop new therapies that target the cellular and molecular mechanisms 
that control the progressive obstructive pulmonary vascular remodelling in PAH. Emerging 
investigations emphasize the importance of recruitment and retention of inflammatory and 
vascular progenitor cells into the vessel wall and highlight roles for C-X-C motif chemokine 
12 (CXCL12, also called stromal cell-derived factor-1) in the progression of experimental 
and human PAH 4-12.  
CXCL12 is able to activate two chemokine receptors, CXCR4 and CXCR7, with different 
downstream signaling pathways. Besides this knowledge, the lung tissue distributions of 
these receptors, and their roles in PAH progression remain unknown 13, 14. To date, among 
the different types of nonpeptidic small molecules targeting the interaction of CXCL12 with 
CXCR4, cyclams and bicyclams such as AMD3100 are well-characterized agents 15. 
However, the CXCR4 antagonist AMD3100 is also known to induce a rapid release of 
CXCL12 from bone marrow stroma to the circulation, leading to the release of stem cells 
into the circulation over their anchorage in bone marrow niches 16. Because CXCR7, which 
binds to the ligand CXCL12 with higher affinity than CXCR4, also contributes to cell 
migration and homing induced by CXCL12, the notion that chemokine blockade could be an 
interesting strategy to be used as an alternative to conventional receptor blockade has 
emerged. In this context, we have recently identified chemokine-neutralizing molecules 
(neutraligands) that prevent CXCL12 from acting on its two main receptors CXCR4 and 
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CXCR7, namely chalcone 4 17, 18 and the recently reported LIT-927, which is the first 
locally and orally active CXCL12 neutraligand with anti-inflammatory effect in a murine 
model of allergic airway hypereosinophilia 19. However, the activity of CXCL12 
neutraligands has not yet been studied in PAH. 
Therefore, in the present study, we explored the activities of chalcone 4 and LIT-927 on 
pulmonary hemodynamics and remodelling processes in cardiac tissues and pulmonary 
arteries in two complementary experimental models of severe pulmonary hypertension 
(PH), namely the monocrotaline- and Sugen-hypoxia-induced models. In order to answer 
these questions, the CXCR4 antagonist AMD3100 was used as a control molecule in our in 
vivo and in vitro studies. 
 
Methods 
All animals were treated in accordance with the Guide for Care and Use of Laboratory 
Animals as adopted by our National Institute of Health and Medical Research (INSERM) 
and approval was granted by the Ethics Committee of the University Paris-Sud, Le Plessis-
Robinson, France (n°01176.01). All experimental studies using human samples comply with 
the Declaration of Helsinki and were approved by the local ethics committee (Comité de 
Protection des Personnes [CPP] Ile-de-France VII). All patients gave informed consent 
before the study. Detailed demographic and clinical characteristics are shown in 
Supplemental Fig. 1A. 
 
Animals and in vivo treatment 
Young male Wistar rats (100 g, Janvier Labs, Saint Berthevin, France) received a single 
subcutaneous injection of monocrotaline (MCT; 60 mg/kg) or vehicle (Supplemental Fig. 
1B). Male rats were used to minimize hormonal effects (e.g., of estrogen). At day-7, MCT-
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injected rats were randomly divided into four groups and treated for 2 weeks with daily 
intraperitoneal (i.p.) injections of vehicle [sodium carboxymethyl cellulose (CMC)], 
AMD3100 (5 mg/kg/day), chalcone 4 or LIT-927 (100 mg/kg/day) in CMC 17, 18, 20, 21. In 
parallel experiments, rats received a single subcutaneous injection of SU5416 (a VEGF-
receptor antagonist; 20 mg/kg) and were exposed to normobaric hypoxia for 3 weeks before 
return to room air (Supplemental Fig. 1C). Five weeks post SU5416 injection, pulsed-wave 
Doppler during transthoracic echocardiography was used to evaluate pulmonary artery 
acceleration time (AT) to right ventricular ejection time (ET) ratio, using Vivid E9 (GE 
Healthcare, Velizy-Villacoublay, France). Then, the rats were randomized to receive i.p. 
vehicle (CMC), AMD3100 (5 mg/kg/day), chalcone 4 or LIT-927 (100 mg/kg/day) in CMC 
for 3 weeks 22. At the end of these protocols, as previously described 23, 24, hemodynamic 
parameters were measured blindly in unventilated anesthetized rats (2.0% isoflurane in 
oxygen) using a closed chest technique. A polyvinyl catheter was introduced into the right 
jugular vein and pushed through the right ventricle into the pulmonary artery to measure the 
mean pulmonary arterial pressure (mPAP). Cardiac output (CO) in rats was blindly 
measured using the thermodilution method. After measurement of hemodynamic 
parameters, the rat was euthanized (by exsanguination under isoflurane) and the thorax was 
opened and the left lung immediately removed and frozen. The right lung was fixed in the 
distended state with formalin buffer. The right ventricular hypertrophy was assessed by the 
Fulton Index and the percentages of muscularized vessels were calculated.  
 
Isolation, culture, and treatment of Human PA-SMCs and pulmonary pericytes 
Primary human PA-SMCs and pericytes were isolated from human lung specimens. For PA-
SMCs isolation, small pieces of freshly isolated arteries were cultured in DMEM media 
supplemented with 15% of foetal calf serum (FCS), 2 mM L-glutamine and antibiotics 24-26. 
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The isolated pulmonary PA-SMCs were strongly positive for alpha-smooth muscle actin (α-
SMA), smooth muscle-specific SM22 protein and calponin, and negative for von 
Willebrand factor and CD31. Human pulmonary pericytes were isolated using an anti-3G5 
antibody, prepared from murine hybridoma (ATCC, Molsheim, France), and anti-IgM 
magnetic beads (Dynal, Life Technologies, Saint-Aubin, France) on lung tissue fragment 
digested by collagenase type I (Gibco, Life Technologies). Pulmonary pericytes were 
cultured in Pericyte medium (Clinisciences, Nanterre, France) and are strongly positive for 
NG2 and PDGF receptor b. PA-SMCs and pericytes were used at passage < 5. PA-SMC 
migration was assessed using the in vitro wound-healing assay with the Ibidi Culture-Insert 
(Ibidi, Nanterre, France). Briefly, confluent monolayers of PA-SMCs were scratch 
wounded, and then incubated with serum (10% FBS) for 24 hours in presence of vehicle 
(DMSO), AMD3100, chalcone 4 or LIT-927 at the indicated concentrations. Images were 
taken using a Zeiss Primo Vert inverted microscope (Zeiss, Marly-le-Roi, France). Pericyte 
migration was assessed using a modified Boyden chamber chemotaxis system as described 
previously 25, 27. Briefly, pulmonary pericytes were stimulated to migrate for 6 hours in 
response to complete medium in presence of vehicle (DMSO), AMD3100, chalcone 4 or 
LIT-927 at the indicated concentrations. Images were taken using KERN OBL-137 
microscope (Kern, Balingen, Germany). 
 
Western blot and Immunostaining  
Cells/tissues were homogenized and sonicated in RIPA buffer containing protease and 
phosphatase inhibitors and 30 µg of protein was used to detect CXCL12, CXCR4, CXCR7, 
NG2, GAPDH and β-actin 24-27 (Supplemental Table 1). Both CXCR4 and CXCR7 
antibodies have been validated using siRNA knockdown assays (Supplemental Fig. 1D). 
Immunohistochemistry and immunofluorescent staining for CXCL12, CXCR4, CXCR7, 
proliferating cell nuclear antigen (PCNA), CD68, 3G5 ganglioside, a-SMA, and SM22 were 
 8 
performed in human and rat lung paraffin sections 24-27 (Supplemental Table 1). Briefly, 
lung sections were deparaffinised and stained with hematoxylin and eosin (Sigma-Aldrich, 
Saint-Quentin Fallavier, France), Picrosirius red, or incubated with the retrieval buffer. 
Then, sections were saturated with blocking buffer and incubated overnight with specific 
antibodies, followed by addition of the corresponding secondary fluorescent-labelled 
antibodies (Thermo Fisher Scientific, Saint-Aubin, France). Nuclei were labelled using 
DAPI (Thermo Fisher Scientific). Mounting was performed using ProLong Gold antifade 
reagent (Thermo Fisher Scientific). Images were taken using a LSM700 confocal 
microscope (Zeiss, Marly-le-Roi, France). Other lung sections were used for 
immunochemistry using vectastain ABC kit according to the manufacturer’s instructions 
(Abcys, Courtaboeuf, France) and counterstained with hematoxylin (Sigma-Aldrich). 
Images were taken using Eclipse 80i microscope (Nikon Instruments, Champigny-sur-
Marne, France).  
 
Statistical analyses 
Statistically significant difference between results was tested using the nonparametric 
Mann-Whitney t-test or one-way ANOVA with Tukey post hoc tests. Significant difference 
was assumed at a p value of < 0.05. Continuous data are expressed as mean ± SEM of at 
least three independent experiments or performed in triplicate or quintuplicate for technical 
replicates. P value < 0.05 was considered statistically significant. Analyses were performed 
using GraphPad Prism v5.0 (La Jolla, CA, USA). 
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Results 
CXCL12, CXCR4 and CXCR7 protein levels are increased in lungs from patients with 
idiopathic PAH (iPAH) and in lungs of rats with established PH 
Immunofluorescence confocal microscopy in combination with Western blotting was first 
used to study the CXCL12, CXCR4, and CXCR7 tissue distribution in lung specimens from 
controls and iPAH patients (Figure 1). Consistent with previously published studies, our 
results indicate a 3.5- to 4-fold increase in CXCL12 and CXCR4 protein levels in lung 
specimens from iPAH patients; in contrast, both signals were weak in vessels from controls 
(Figure 1A-B). Whereas CXCR4 immunostaining was predominantly localized within walls 
of remodelled vessels, CXCL12 immunoreactivity was noted in the dysfunctional 
pulmonary endothelium and alveolar macrophages (Figure 1A-B). Our findings also reveal 
a 1.5-fold increase in CXCR7 protein levels in lung homogenates that concerns all layers of 
the remodelled arterial walls of iPAH patients, contrasting with its low immunoreactivity in 
control lung specimens (Figure 1C).  
The two most widely used and complementary animal models of PH were next used to 
examine the lung protein expression patterns of CXCL12, CXCR4, and CXCR7. Consistent 
with our findings obtained with human specimens, we show here that CXCL12 (Figure 
2A), and its two cognate receptors (Figure 2B-C) were substantially increased in lungs from 
rats with established PH induced by a single subcutaneous injection of either MCT or of 
SU5416 followed by chronic hypoxia when compared with control rat lungs. 
 
Chronic treatment with AMD3100, chalcone 4, or LIT-927 attenuates established PH in 
MCT-injected rats 
To determine the effect of treatments with either the CXCR4 antagonist AMD3100 or each 
of the CXCL12 neutraligands against the progression of established PH in MCT-injected 
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rats, pulmonary hemodynamics and structural changes in the pulmonary arteries and cardiac 
tissues were studied (Figure 3 and Supplemental Fig. 1B and 2A). Serum levels of 
circulating CXCL12 were increased in MCT-injected rats, a phenomenon totally abolished 
with chronic treatments with the neutraligands chalcone 4 or LIT-927 versus vehicle 
(Supplemental Fig. 2B).  
Twenty-one days post-MCT injection, a marked increase in values of mPAP, total 
pulmonary vascular resistance (TPVR) (Figure 3A), and in RV/(LV+S) ratio (Figure 3B) 
were found in MCT-injected rats treated with vehicle when compared with control rats. 
Although no changes were found with AMD3100 treatment, MCT-injected rats treated with 
chalcone 4 or LIT-927 exhibited reduced mPAP associated with reduced TPVR elevation 
when compared with MCT-injected rats treated with vehicle (Figure 3A). In contrast to 
MCT-injected rats treated with AMD3100 or with chalcone 4, a substantial decrease in 
values of Fulton index (assessing right ventricular hypertrophy) was found in MCT-injected 
rats treated with LIT-927 when compared with vehicle (Figure 3B). Of note, no differences 
were found in values of systemic pressures (mean systemic blood pressure:  90.7 ± 5.5, 90.4 
± 11.8, 87.8 ± 6.7, 87.5 ± 13.9, 80.8 ± 14.4, respectively, NS) between control rats and 
MCT-injected rats treated with vehicle, AMD3100, chalcone 4, or LIT-927. 
Consistent with these results, the percentage of muscularized distal pulmonary arteries 
(Figure 3C) that was increased 8-fold in MCT-injected rats treated with vehicle when 
compared with control rats, was substantially decreased in MCT-injected rats treated with 
chalcone 4 or LIT-927 (Figure 3C). Furthermore, we also noted a reduced increase in the 
number of PCNA+ cells per lung vessel in MCT-injected rats treated with AMD3100, 
chalcone 4, or LIT-927 when compared with vehicle (Figure 3C). In addition, we found a 
reduced collagen deposition in the right ventricle of MCT-injected rats treated with 
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chalcone 4, or LIT-927 as compared with MCT-injected rats treated with vehicle, but not in 
MCT-injected rats treated with AMD3100 (Figure 3D). 
 
Chronic treatment with AMD3100, chalcone 4, or LIT-927 attenuates established PH in 
SuHx rats 
To validate our findings in the MCT rat model, a 3-week daily treatment of SuHx rats with 
AMD3100, chalcone 4 or LIT-927 started 5 weeks post-SU5416 injection was next 
performed (Figure 4 and Supplemental Fig. 1C). Consistent with the MCT rat model, a 
substantial increase in the circulating levels of CXCL12 was found in the SuHx rat model of 
severe PH, a phenomenon totally abolished with chronic treatment of SuHx rats with either 
of the neutraligands as compared with vehicle (Supplemental Fig. 2C).  
Eight weeks post-SU5416 injection, SuHx rats developed more severe experimental PH 
versus MCT-injected rats, as reflected by a marked increase in mPAP and in the ratio of 
acceleration time (AT) to ejection time (ET) (Supplemental Fig. 2A and D), and a decrease 
in cardiac output (CO) (Figure 4A). Although no significant changes were found in mPAP 
values in this severe model, SuHx rats treated with AMD3100, chalcone 4 or LIT-927 
exhibited reduced TPVR elevation when compared to SuHx rat-treated with vehicle (Figure 
4A). Furthermore, right ventricular hypertrophy, pulmonary vascular remodelling, and RV 
fibrosis were also more prominent in the SuHx versus MCT model (Figure 3 and 4, panels 
B-D).  
Interestingly, in contrast to the AMD3100-treated MCT rats, AMD3100-treated SuHx rats 
exhibited reduced TPVR elevation and right ventricular hypertrophy as compared with 
SuHx rats treated with vehicle (Figure 3 and 4, panels A-B). Of note, no differences were 
also found in values systemic pressures (mean systemic blood pressure: 94.4 ± 5.7, 100.8 ± 
5.0, 102.7 ± 14.0, 100.3 ± 10.9, 103.2 ± 5.9, respectively, NS) between controls and SuHx 
rats treated with vehicle, AMD3100, chalcone 4, or LIT-927. 
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In addition, our data also indicate that the pulmonary arterial muscularization, and the 
number of PCNA+ cells per vessel were substantially decreased in SuHx rats treated with 
AMD3100, chalcone 4 or LIT-927 when compared with vehicle (Figure 4C-D and 
Supplemental Fig. 2E). In contrast to SuHx rats treated with chalcone 4 or LIT-927, no 
difference in collagen deposition in the right ventricle was observed in SuHx rats treated 
with AMD3100 (Figure 4D) 
 
CXCL12 neutraligands inhibit the migration of PA-SMCs and pericytes in vitro  
The CXCL12/CXCR4/CXCR7 axis directly contributes to cell migration, a phenomenon 
that plays a key role in the muscularization of distal pulmonary arteries in PAH 9, 25. First, 
we have validated that cultured human PA-SMCs and pulmonary pericytes express the 
CXCR4 and CXCR7 receptors (Supplement Fig. 3A) and that chalcone 4 and LIT-927 
attenuate the CXCL12-induced phosphorylation of ERK and AKT (Supplement Fig. 3B-
D). We therefore studied the effects of AMD3100, chalcone 4 and LIT-927 in vitro on 
migration of human PA-SMCs and pulmonary pericytes in primary cultures (Figure 5). In 
contrast to AMD3100, CXCL12 neutralization with chalcone 4 or LIT-927 inhibits the 
migration of cultured human PA-SMCs in a concentration-dependent manner (Figure 5A). 
Consistent with these findings, human pulmonary pericytes also exhibited decreased 
migration when exposed to chalcone 4 or LIT-927, with no effect of AMD3100 (Figure 
5B).  
 
CXCL12 neutraligands decrease pericyte coverage of vessels and macrophage infiltration 
in lungs from MCT-injected and SuHx rats 
To validate our in vitro observations, we then localized and quantified pericytes in lungs of 
MCT-injected and SuHx rats treated either with vehicle, AMD3100, chalcone 4, or LIT-927 
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(Figure 6). Western blotting and immunohistological studies revealed a substantial 
reduction in pericyte numbers around remodelled vessels in lungs of MCT and SuHx rats 
treated with chalcone 4, or LIT-927 when compared with lungs of MCT-injected and SuHx 
rats treated with vehicle (Figure 6A-B).  
Because CXCL12 is well established to be responsible for recruiting macrophages 28, 29, we 
finally evaluated the effect of chronic treatments with AMD3100 and the neutraligands on 
macrophage infiltration in lungs of controls and treated rats. Our data indicate a substantial 
decrease in CD68 positive cells in both MCT-injected and SuHx rats treated with chalcone 4 
and LIT-927 when compared with vehicle (Figure 6C-D). Furthermore, chronic treatment 
with AMD3100 decreased the number of CD68 positive cells only in the SuHx rats (Figure 
6D).  
 
Discussion 
Pulmonary arterial hypertension is well characterized by progressive narrowing and 
obliteration of the pulmonary vasculature due to intrinsic proliferative potential and 
accumulation of resident pulmonary vascular cells and inflammatory cells in the vascular 
wall. However, the currently available drugs do not target these processes. Here, we report 
that neutralization of CXCL12 with small chemical compounds, the neutraligands chalcone 
4 and LIT-927, improved pulmonary hemodynamics as well as lung and cardiac structure in 
rats with established PH in two complementary and well-established models of severe PH. 
In addition, we obtained in vivo and in vitro evidence supporting the notion that the 
neutralization of CXCL12 is more effective than the conventional CXCR4 blockade with 
AMD3100. 
This present translational research investigated the activity of two CXCL12 neutraligands 
against established PH in two complementary animal models of severe PH 18-20. Hence, we 
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firstly conducted immunofluorescence and confocal analyses of CXCL12, CXCR4, and 
CXCR7 protein levels in lungs from patients with iPAH and from rats with established PH. 
Interestingly, we not only confirmed a more intense immunoreactivity for CXCL12 and 
CXCR4 in lungs from patients with iPAH 12 and from rodents with established PH 4, 6, 21, 30, 
31, but also highlighted an overexpression of CXCR7. Notably, we noted that the 
dysfunctional pulmonary endothelium and the alveolar macrophages are two local sources 
of CXCL12 in lungs of PAH patients and that PA-SMCs and several cells in the adventitia 
overexpress CXCR4 and CXCR7. We thus evaluated the effect of CXCL12 neutralization in 
MCT-injected and SuHx rats against established PH and found that daily treatments with 
either chalcone 4 or LIT-927, more effectively than AMD3100, attenuate pulmonary 
hemodynamics and lung vascular remodelling. Of interest to note is that the efficacy of 
AMD3100, chalcone-4, and LIT-927 treatments against established PH is more or less 
pronounced depending on the animal model, perhaps because of the difference in the 
rapidity of disease progression or in the pathogenic mechanisms involved and their 
dynamics. 
Herein, our present study supports that CXCL12 neutralization has better beneficial effect 
than the conventional CXCR4 blockade with AMD3100 in both MCT and SuHx rat models 
of severe PH that are characterized by a progressive and irreversible pulmonary vascular 
remodeling. Even if these two animal models do not reproduce the full spectrum of changes 
seen in lung specimens from iPAH patients, they are very valuable to validate new targets 
and/or treatments and to give insights into the disease mechanisms 32. The current results are 
in line with the results obtained by our group and others showing that combined antagonism 
of CXCR4 and CXCR7 attenuates the chronic-hypoxia-induced PH 6, 30, 31, and also with the 
results of Farkas et al. showing that CXCR4 inhibition with AMD3100 is able to prevent the 
increased muscularization and partially the obliteration of pulmonary arteries in the SuHx 
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model 21. Consistent with these in vivo observations, our in vitro findings obtained with 
primary cultures of human PA-SMCs and pulmonary pericytes indicate that CXCL12 
neutralization, in contrast to CXCR4 antagonism with AMD3100, substantially inhibits cell 
migration in a concentration-dependent manner. Because accumulation of both PA-SMCs, 
pulmonary pericytes and inflammatory cells in walls of distal pulmonary arteries increases 
substantially during disease progression 7, 9, 24, 25, 33, potent and selective inhibitors of the 
CXCL12/CXCR4/CXCR7 axis could open new therapeutic options in PAH, especially 
neutraligands which prevent binding of CXCL12 to the receptors CXCR4 and CXCR7 19, 20. 
These neutraligands are, indeed, small selective molecules that can rapidly neutralize 
CXCL12 by direct binding and thus prevent CXCL12 from activating its CXCR4 and 
CXCR7 receptors 18-20. In addition to reduce migration of human PA-SMCs and pulmonary 
pericytes, chalcone 4 and LIT-927 attenuate the proliferation of human PA-SMCs in vitro 
(Supplemental Fig. 3E) and reduce numbers of macrophages in lungs from MCT-injected 
and SuHx rats. Remarkably, macrophages have been implicated in the pathogenesis of PAH 
34-37. This mode of action that allow the blockade of CXCL12 without any direct effect on 
the two receptors favors cell homeostasis and the fact that these molecules influence several 
mechanisms involved in PAH pathobiology are particularly promising in this context.  
It is now well established that CXCL12 expression is upregulated by hypoxia, as a result of 
HIF-1 and HIF-2 binding to its promoter 38, 39. However, inﬂammatory mediators such as 
IL-1 an IL-6 can also induce CXCL12 expression in a CCAAT/enhancer binding protein b 
(c/EBPb)-dependent manner 40. In this context, the protective effect of CXCL12 
neutralization might also be partly related to attenuation of other possible pathogenic 
pathways involved in PAH, such as the macrophage migration inhibitory factor (MIF) 
signaling pathways 41, 42. Indeed, CXCL12 neutralization substantially reduces circulating 
levels of MIF, but does not affect levels of CXCL11 or CCL2 in the serum of rats treated 
 16 
with chalcone-4, LIT927 (Supplemental Table 2). Additionally, the promoter region of 
CXCL12 contains binding sites for several transcriptional factors, including among others: 
Sp1, AP1, PARP1 and NF-kB 43. Further investigations are thus needed to better understand 
the molecular mechanisms underlying the CXCL12 overexpression in lungs of PAH. 
Although the CXCL12/CXCR4 axis plays an important role in the onset and progression of 
the disease 4-12, little is known about the role of CXCR7 in PAH. Interestingly, CXCR7 
appears to be critical for both the cardiovascular system development and vascular 
homeostasis in animal models. Decreased CXCR7 expression in zebrafish embryos inhibits 
blood vessel formation 44, and its loss in mice causes early postnatal mortality as a result of 
myocardial degeneration and heart vessel damage 45. In parallel, CXCR7 is also known to 
play an integral role in tumor progression by inducing tumor cell proliferation, adhesion, 
invasion, as well as tube formation in vitro and promotes tumor growth in vivo 46-49. 
Studying the role of CXCR7 in PAH was not in the scope of this study, but will deserve 
further investigations.  
 
In conclusion, our data demonstrate that the CXCL12/CXCR4/CXCR7 axis plays a central 
role in PAH and that CXCL12 neutralization appears to be an interesting strategy to be used 
as an alternative to conventional CXCR4 or CXCR7 blockade. Moreover, we found that 
these beneficial effects of CXCL12 neutraligands were associated with decreased pericyte 
coverage of remodelled pulmonary arterioles and reduced macrophage infiltration in lungs 
of MCT-injected and SuHx rats. Finally, this study offers important physiopathological 
insight into the role of the CXCL12/CXCR4/CXCR7 pathway and may have important 
implications for human PAH. 
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Figure Legends:  
Figure 1: Increased expressions of CXCL12, CXCR4, and CXCR7 in lungs patients with 
idiopathic pulmonary arterial hypertension (iPAH). (A) Representative images of CXCL12 (red), 
(B) CXCR4 (red), and (C) CXCR7 (red) staining with SM22 (green) and DAPI (blue) and Western 
blots with quantification of the CXCL12:GAPDH, CXCR4:GAPDH, and CXCR7:GAPDH ratios in 
lungs from control subjects and iPAH. Comparisons were made using the nonparametric Mann-
Whitney t-test. Scale bar = 50 μm in all sections. Horizontal lines display the mean ± SEM (n = 5-7). 
* p-value <0.05, *** p-value <0.001 compared with control. AU = arbitrary unit; DAPI = 4’,6-
diamidino-2-phenylindole. 
Figure 2: Increased expressions of CXCL12, CXCR4, and CXCR7 in lungs of monocrotaline 
(MCT)-injected and sugen/hypoxia (SuHx) rats with established pulmonary hypertension (PH). 
(A) Representative images of CXCL12 (red), (B) CXCR4 (red), and (C) CXCR7 (red) staining with α-
smooth muscle actin (α-SMA; green) and DAPI (blue) and Western blots with quantification of the 
CXCL12:GAPDH, CXCR4:GAPDH, and CXCR7:GAPDH ratios in lungs from control, MCT-injected 
and SuHx rats (at Week-3 and Week-5, respectively). Scale bar = 50 μm in all sections. Horizontal 
lines display the mean ± SEM (n = 5-7). Comparisons were made using the nonparametric Mann-
Whitney t-test. * p-value <0.05, ** p-value <0.01, *** p-value <0.001 compared with control. AU = 
arbitrary unit; DAPI = 4’,6-diamidino-2-phenylindole. 
Figure 3: Efficacy of AMD3100, chalcone 4, and LIT-927 in the monocrotaline (MCT) rat model 
of severe PH. (A) Values of mean pulmonary arterial pressure (mPAP), cardiac output (CO), total 
pulmonary vascular resistance (TPVR), and of (B) Fulton index in vehicle-, AMD3100-, chalcone 4-, 
and LIT-927 treated rats. (C) Representative images of haematoxylin and eosin (H&E)-, α-smooth 
muscle (SM) actin- and proliferating cell nuclear antigen (PCNA)-stained sections of distal 
pulmonary arteries and quantification of the percentage of muscularized distal pulmonary arteries 
and of the number of PCNA positive cells per vessel in lungs of vehicle-, AMD3100-, chalcone 4-, 
and LIT-927 treated rats. (D) Representative images of picrosirius staining of tissue section of right 
ventricle myocardium of control and monocrotaline (MCT)-injected rats treated with vehicle- 
AMD3100-, chalcone 4-, and LIT-927. Horizontal lines display the mean ± SEM (n = 4-5). 
Comparisons were made using 1-way ANOVA with Tukey’s post hoc tests. * p-value < 0.05; ** p-
value < 0.01; *** p-value < 0.001; **** p-value < 0.0001 versus control rats. # p-value < 0.05; ## p-
value < 0.01; ### p-value < 0.001; #### p-value < 0.0001 versus vehicle treated rats exposed to 
MCT. $ p-value < 0.05; $$ p-value < 0.01;  $$$ p-value < 0.001; versus AMD3100-treated rats 
exposed to MCT Scale bar = 50 μm in all sections. AU = arbitrary unit; LV = left ventricle; RV = right 
ventricle; S = septum. 
Figure 4: Efficacy of AMD3100, chalcone 4, and LIT-927 in the Sugen-hypoxia (SuHx) rat 
model of severe PH. (A) Values of mean pulmonary arterial pressure (mPAP), cardiac output (CO), 
total pulmonary vascular resistance (TPVR), and of (B) Fulton index in vehicle-, AMD3100-, 
chalcone 4-, and LIT-927 treated SuHx rats. (C) Representative images of haematoxylin and eosin 
(H&E)-, α-smooth muscle (SM) actin- and proliferating cell nuclear antigen (PCNA)-stained sections 
of distal pulmonary arteries and quantification of the percentage of muscularized distal pulmonary 
arteries and of the number of PCNA positive cells per vessel in lungs of vehicle-, AMD3100-, 
chalcone 4-, and LIT-927 treated SuHx rats. (D) Representative images of picrosirius staining of 
tissue section of right ventricle myocardium of control and SuHx rats treated with vehicle- AMD3100-
, chalcone 4-, and LIT-927. Horizontal lines display the mean ± SEM (n = 4). Comparisons were 
made using 1-way ANOVA with Tukey’s post hoc tests. *** p-value < 0.001; **** p-value < 0.0001 
versus control rats. # p-value < 0.05; ## p-value < 0.01; ### p-value < 0.001; #### p-value < 0.0001 
versus vehicle treated SuHx rats. $ p-value < 0.05; $$ p-value < 0.01; $$$ p-value < 0.001; $$$$ p-
value < 0.0001 versus AMD3100-treated SuHx rats. Scale bar = 50 μm in all sections. AU = arbitrary 
unit; LV = left ventricle; RV = right ventricle; S = septum. 
Figure 5: CXCL12 neutralization inhibits the migration potentials of Human PA-SMCs and 
pulmonary pericytes in vitro. (A) Representative images of wound healing assay and 
quantification of the surface covered by human PA-SMCs after 0, 12, and 24 hours exposed or not 
to AMD3100, chalcone 4, or LIT-927 at the indicated doses. (B) Representative images and 
quantification of the in vitro migration of pulmonary pericytes in the modified Boyden exposed or not 
to AMD3100, chalcone 4, or LIT-927 at the indicated doses for 6 hours. Horizontal lines display the 
mean ± SEM (n = 4-6). Comparisons were made using 1-way ANOVA with Tukey’s post hoc tests. * 
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p-value < 0.05; ** p-value < 0.01; **** p-value < 0.0001 versus vehicle-treated cells. $ p-value < 
0.05; $$ p-value < 0.01; $$$ p-value < 0.001; $$$$ p-value < 0.0001 versus AMD3100-treated cells. 
Scale bar = 500 μm in all sections. AU = arbitrary unit. 
Figure 6: CXCL12 neutralization decreases pericyte coverage of vessels as well as 
macrophage infiltration in lungs of MCT-injected and SuHx rats. (A) Representative Western 
blot and quantification of the NG2: b-actin ratios in lungs from control, MCT-injected and SuHx rats 
treated or not with vehicle, AMD3100, chalcone 4, or LIT-927. (B) Representative images of 3G5 
(white) with SM22 (green) and DAPI (blue) and quantification of the number of 3G5 positive cells per 
vessels in lungs of MCT-injected and SuHx rats treated or not with vehicle, AMD3100, chalcone 4, or 
LIT-927. Representative images of CD68 and quantification of the number of CD68 positive cells per 
vessel in lungs of MCT-injected (C) and SuHx- (D) rats treated or not with vehicle, AMD3100, 
chalcone 4, or LIT-927. Horizontal lines display the mean ± SEM (n = 4-5). * p-value < 0.05; *** p-
value < 0.001; **** p-value < 0.0001 versus controls. Comparisons were made using 1-way ANOVA 
with Tukey’s post hoc tests. # p-value < 0.05; ## p-value < 0.01; ### p-value < 0.001; #### p-value 
< 0.0001 versus vehicle treated rats. $$ p-value < 0.01; $$$ p-value < 0.001 versus AMD3100-
treated cells.  AU = arbitrary unit; DAPI = 4’,6-diamidino-2-phenylindole. 
 
